Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

Ironwood Pharmaceuticals Earnings Perspective: Return On Capital Employed

According to Benzinga Pro data Ironwood Pharmaceuticals (NASDAQ:IRWD) posted a 25.91% decrease in earnings from Q3. Sales, however, increased by 12.9% over the previous quarter to $117.13 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Ironwood Pharmaceuticals is not utilizing their capital as effectively as possible. In Q3, Ironwood Pharmaceuticals earned $55.84 million and total sales reached $103.75 million.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.